Loading clinical trials...

Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin

A Randomized, Open-label, 3-way Crossover Phase I Study in Type 2 Diabetes Mellitus Patients Treated With Metformin to Evaluate the Pharmacokinetics and Pharmacodynamics of Simvastatin During Coadministration With AZD1656 and to Evaluate the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin

NCT01096940•AstraZeneca

View on ClinicalTrials.gov

Summary

To assess the pharmacokinetics of AZD1656 during coadministration with Simvastatin.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with a clinical diagnosis of T2DM for at least 1 year, treated with any metformin or metformin with one other oral anti-diabetic drug (OAD)
•Body mass index between greater than or equal to 19 and less than or equal to 42 kg/m2
•HbA1c greater than 6.5% at enrollment

Exclusion Criteria

•Clinically significant illness or clinically relevant trauma, as judged by the Investigator, within 2 weeks before the first administration of the IP
•Significant cardiovascular event within the last 6 months prior to enrollment (eg, myocardial infarction/acute coronary syndrome, revascularisation procedure, stroke or transient ischaemic attack) or heart failure New York Heart Association (NYHA) class III-IV

Locations (1)

Research Site

San Antonio, Texas, United States

Key Dates

Start Date

March 1, 2010

Primary Completion Date

August 1, 2010

Completion Date

August 1, 2010

Last Updated

November 8, 2010

Enrollment

ACTUAL participants

Conditions

Type 2 Diabetes Mellitus

Interventions

AZD1656

DRUG

simvastatin

DRUG

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITINGNA

Achieving Routine Intervention and Screening for Emotional Health

NCT06887049

Type 2 Diabetes Mellitus (T2DM)Diabetes Distress

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 8, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Achieving Routine Intervention and Screening for Emotional Health

Human Immunodeficiency Virus (HIV) Food Insecurities

A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus

Impact of the New Generation Anti-diabetic Drugs on Diabetic Retinopathy

Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease